MX344865B - Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos. - Google Patents
Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos.Info
- Publication number
- MX344865B MX344865B MX2009001130A MX2009001130A MX344865B MX 344865 B MX344865 B MX 344865B MX 2009001130 A MX2009001130 A MX 2009001130A MX 2009001130 A MX2009001130 A MX 2009001130A MX 344865 B MX344865 B MX 344865B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- methylami
- naphthyridine
- pyrrolidinyl
- thiazolyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describen los métodos para el tratamiento, prevención o manejo de padecimientos hematológicos, tal como leucemia. Los métodos engloban la administración de SNS-595. También se proporcionan métodos de tratamiento que usan este compuesto con quimioterapía, terapia con radiación, terapia hormonal, terapia biológica o inmunoterapia. En ciertas modalidades, el método de tratamiento comprende administrar SNS-595 en combinación con Ara-C. También se describen las composiciones farmacéuticas y las formas de dosis unitarias únicas adecuadas para usarse en los métodos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83523906P | 2006-08-02 | 2006-08-02 | |
US87376006P | 2006-12-08 | 2006-12-08 | |
PCT/US2007/017344 WO2008016702A2 (en) | 2006-08-02 | 2007-08-02 | Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2009001130A MX2009001130A (es) | 2009-05-13 |
MX344865B true MX344865B (es) | 2016-12-19 |
Family
ID=38859094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009001130A MX344865B (es) | 2006-08-02 | 2007-08-02 | Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos. |
Country Status (12)
Country | Link |
---|---|
US (3) | US20080063642A1 (es) |
EP (2) | EP2049109B1 (es) |
JP (4) | JP2009545601A (es) |
CA (1) | CA2659861A1 (es) |
CY (1) | CY1119309T1 (es) |
DK (1) | DK2049109T3 (es) |
ES (1) | ES2556677T3 (es) |
HU (1) | HUE026693T2 (es) |
MX (1) | MX344865B (es) |
PL (1) | PL2049109T3 (es) |
SI (1) | SI2049109T1 (es) |
WO (1) | WO2008016702A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1725233T3 (da) | 2004-03-15 | 2011-03-14 | Sunesis Pharmaceuticals Inc | Farmaceutisk sammensætning omfattende SNS-595 og anvendelse deraf |
US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
KR20090021215A (ko) | 2006-06-12 | 2009-02-27 | 선에시스 파마슈티컬스 인코포레이티드 | 암의 치료를 위한 화합물 및 조성물 |
WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
CN103720701A (zh) | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
US20110008371A1 (en) * | 2007-12-10 | 2011-01-13 | Sunesis Pharmaceuticals, Inc | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders |
RU2548031C2 (ru) | 2008-12-31 | 2015-04-10 | Санесис Фармасьютикалз, Инк. | Способ получения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
WO2011056566A2 (en) * | 2009-10-26 | 2011-05-12 | Sunesis Pharmaceuticals, Inc. | Compounds and methods for treatment of cancer |
EP2506840B1 (en) | 2009-12-04 | 2021-01-06 | Oncoimmune Inc. | Uses of hypoxia-inducible factor inhibitors |
RU2550663C2 (ru) * | 2013-02-13 | 2015-05-10 | Владимир Владимирович Савостьянов | Способ гормонально-лучевой подготовки больных хроническим лимфолейкозом к последующей химиотерапии |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
CR20170086A (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinación con anticuerpos anti-cd38 |
CA2969717A1 (en) * | 2014-12-04 | 2016-06-09 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
BR112017024727A2 (pt) | 2015-05-18 | 2018-07-31 | Syn Nat Products Entpr Llc | cocristal, composição farmacêutica, método de tratamento de uma doença em um indivíduo e processo de produção de um cocristal |
CN108136218B (zh) | 2015-05-20 | 2022-12-13 | 詹森生物科技公司 | 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体 |
WO2016205782A1 (en) * | 2015-06-19 | 2016-12-22 | Syn-Nat Products Enterprise LLC | Composition containing carboplatin and use |
AU2016279099B2 (en) | 2015-06-19 | 2021-09-23 | Syn-Nat Products Enterprise LLC | Pharmaceutical composition of carboplatin based co-crystals and use thereof |
JP6816038B2 (ja) | 2015-06-22 | 2021-01-20 | ヤンセン バイオテツク,インコーポレーテツド | 抗cd38抗体及びサバイビン阻害剤による血液悪性疾患の併用療法 |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
AU2016284816B2 (en) | 2015-06-25 | 2021-10-07 | Syn-Nat Products Enterprise LLC | Pharmaceutical co-crystal composition and use thereof |
MA53356B1 (fr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5382525A (en) * | 1992-11-27 | 1995-01-17 | American Air Liquide | Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases |
US5360352A (en) * | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
JP3391796B2 (ja) | 1994-06-14 | 2003-03-31 | 大日本製薬株式会社 | 新規化合物、その製法および抗腫瘍剤 |
JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
AU739350B2 (en) * | 1997-06-05 | 2001-10-11 | University Of Texas System, The | APAF-1, the CED-4 human homolog, an activator of caspase-3 |
US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
US6670144B1 (en) * | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
WO2000050453A1 (en) * | 1999-02-26 | 2000-08-31 | The Johns Hopkins University | A novel inhibitor of programmed cell death |
US7163801B2 (en) * | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
DK1725233T3 (da) * | 2004-03-15 | 2011-03-14 | Sunesis Pharmaceuticals Inc | Farmaceutisk sammensætning omfattende SNS-595 og anvendelse deraf |
US20050222267A1 (en) * | 2004-04-01 | 2005-10-06 | Truong Van H | Solution based methacholine formulations |
WO2007028171A1 (en) | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
-
2007
- 2007-08-02 JP JP2009522883A patent/JP2009545601A/ja active Pending
- 2007-08-02 MX MX2009001130A patent/MX344865B/es active IP Right Grant
- 2007-08-02 WO PCT/US2007/017344 patent/WO2008016702A2/en active Application Filing
- 2007-08-02 ES ES07811049.1T patent/ES2556677T3/es active Active
- 2007-08-02 EP EP07811049.1A patent/EP2049109B1/en not_active Revoked
- 2007-08-02 EP EP15189348.4A patent/EP3025712A1/en not_active Withdrawn
- 2007-08-02 US US11/890,196 patent/US20080063642A1/en not_active Abandoned
- 2007-08-02 CA CA002659861A patent/CA2659861A1/en not_active Abandoned
- 2007-08-02 SI SI200731723T patent/SI2049109T1/sl unknown
- 2007-08-02 DK DK07811049.1T patent/DK2049109T3/en active
- 2007-08-02 HU HUE07811049A patent/HUE026693T2/hu unknown
- 2007-08-02 PL PL07811049T patent/PL2049109T3/pl unknown
-
2013
- 2013-09-25 JP JP2013198807A patent/JP2014040437A/ja active Pending
-
2014
- 2014-08-15 US US14/461,271 patent/US20150190380A1/en not_active Abandoned
-
2015
- 2015-11-09 JP JP2015219880A patent/JP6189911B2/ja not_active Expired - Fee Related
- 2015-12-15 CY CY20151101147T patent/CY1119309T1/el unknown
-
2016
- 2016-06-03 US US15/173,506 patent/US20170119745A1/en not_active Abandoned
-
2017
- 2017-08-03 JP JP2017150849A patent/JP2017226683A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
DK2049109T3 (en) | 2016-01-11 |
SI2049109T1 (sl) | 2016-04-29 |
US20150190380A1 (en) | 2015-07-09 |
HUE026693T2 (hu) | 2016-07-28 |
JP2016053070A (ja) | 2016-04-14 |
JP6189911B2 (ja) | 2017-08-30 |
EP3025712A1 (en) | 2016-06-01 |
ES2556677T3 (es) | 2016-01-19 |
PL2049109T3 (pl) | 2016-05-31 |
US20080063642A1 (en) | 2008-03-13 |
CY1119309T1 (el) | 2018-02-14 |
JP2017226683A (ja) | 2017-12-28 |
JP2009545601A (ja) | 2009-12-24 |
WO2008016702A3 (en) | 2008-03-20 |
WO2008016702A2 (en) | 2008-02-07 |
MX2009001130A (es) | 2009-05-13 |
CA2659861A1 (en) | 2008-02-07 |
JP2014040437A (ja) | 2014-03-06 |
EP2049109B1 (en) | 2015-11-18 |
EP2049109A2 (en) | 2009-04-22 |
US20170119745A1 (en) | 2017-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX344865B (es) | Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1(2-tiazolil)-1,8-naftiridina-3-ca rboxilico para el tratamiento de ciertos padecimientos hematologicos. | |
WO2009075841A3 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders | |
UA94062C2 (en) | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of leukemia | |
IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
EP2460522A3 (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
MX2007006063A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de lesion al sistema nervioso central. | |
HUS1600021I1 (hu) | MEK inhibitorok és módszerek azok felhasználására | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
WO2007149406A8 (en) | Modified coagulation factor ix polypeptides and use thereof for treatment | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
EP2056818A4 (en) | COMPOSITIONS AND METHODS FOR NEUROPROTECTION | |
EP2479290A3 (en) | Methods for the administration of iloperidone | |
MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
ATE442142T1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
WO2007097989A3 (en) | A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer | |
MX2010004350A (es) | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. | |
MX2010005009A (es) | Uso de compuestos inmunomoduladores para el tratamiento de trastornos asociados con disfunciones endoteliales. | |
WO2006138589A3 (en) | Opioid receptor ligands | |
AU2013219242C1 (en) | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer | |
TW200500073A (en) | Pharmaceutical composition comprising an indolopyrrolocarbazole derivative and use thereof | |
DK2091919T3 (da) | Derivater af 18-amino-substituerede analoge af geldamycinhydroquinon med cytotoksisk aktivitet til behandling af cancer | |
UA90264C2 (ru) | Три(цикло)замещенные амиды, фармацевтическая композиция, способы лечения и профилактики, способ получения соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |